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Cardiac molecular pathways 
influenced by doxorubicin 
treatment in mice
Ben F. Bulten1,2, Martina sollini  3,6, Roberto Boni4,6, Katrin Massri5,6, Lioe-Fee de Geus-Oei1,7,  
Hanneke W. M. van Laarhoven8, Riemer H. J.A. slart1,9 & Paola A. Erba6,9
Doxorubicin (DOX) is a potent chemotherapeutic with distinct cardiotoxic properties. Understanding 
the underlying cardiotoxic mechanisms on a molecular level would enable the early detection of 
cardiotoxicity and implementation of prophylactic treatment. Our goal was to map the patterns 
of different radiopharmaceuticals as surrogate markers of specific metabolic pathways induced by 
chemotherapy. Therefore, cardiac distribution of 99mTc-sestamibi, 99mTc-Annexin V, 99mTc-glucaric acid 
and [18F]FDG and cardiac expression of Bcl-2, caspase-3 and -8, TUNEL, HIF-1α, and p53 were assessed 
in response to DOX exposure in mice. A total of 80 mice (64 treated, 16 controls) were evaluated. All 
radiopharmaceuticals showed significantly increased uptake compared to controls, with peak cardiac 
uptake after one (99mTc-Annexin V), two (99mTc-sestamibi), three ([18F]FDG), or four (99mTc-glucaric acid) 
cycles of DOX. Strong correlations (p < 0.01) were observed between 99mTc-Annexin V, caspase 3 and 8, 
and TUNEL, and between [18F]FDG and HIF-1α. This suggests that the cardiac DOX response starts with 
apoptosis at low exposure levels, as indicated by 99mTc-Annexin V and histological apoptosis markers. 
Late process membrane disintegration can possibly be detected by 99mTc-sestamibi and 99mTc-glucaric 
acid. [18F]FDG signifies an early adaptive response to DOX, which can be further exploited clinically in 
the near future.
Doxorubicin (DOX) is a glycosidic antibiotic belonging to the class of anthracyclines. It is a highly effective 
cytotoxic drug used against both solid and hematological cancer types1. The counterpart of this powerful anti-
neoplastic effect is that DOX (and anthracyclines in general) induces apoptosis in noncancerous cells, including 
cardiomyocytes. This causes acute and chronic cardiotoxicity (termed anthracycline-induced cardiotoxicity, or 
AIC), which negatively impacts patient outcome2.
Among the key cardiotoxic effects of DOX are the inhibition of topoisomerase IIβ, the formation of reac-
tive oxygen species (ROS) accompanied by depletion of endogenous antioxidants, and the subsequent triggering 
of the intrinsic mitochondria-dependent and extrinsic death receptor apoptotic pathway3,4. As a result, caspase 
3 is activated and, collectively, a subsequent cascade of events typical of apoptosis occurs. The cascade can be 
divided into three phases: an early phase consisting of caspase activation and phosphatidylserine (PS) expression; 
a mid-phase consisting of DNA fragmentation, chromatin condensation, and membrane phospholipid metab-
olization; and a late stage characterized by membrane blebbing and cell shrinkage5. These mutations in cardio-
myocyte homeostasis underlie the pattern of subclinical cardiotoxicity. A better understanding of the involved 
mechanisms offers the opportunity for multi-targeted exploration of early AIC, leading to the development of 
non-invasive and quantitative detection tools to optimize a patient-based approach.
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Available imaging techniques such as echocardiography, multigated radionuclide angiography (MUGA), 
and cardiac magnetic resonance imaging (CMR) have been used to accurately and reproducibly evaluate 
anthracycline-induced changes. However, the anatomy-based parameters provided by these approaches only 
detect late-phase AIC alterations, and have low sensitivity in detecting subclinical myocardial dysfunction1,6. 
Furthermore, with the increasing number of cancer survivors, there is a growing need to change the paradigm 
from the current method of simply measuring reduction of myocardial function to early identification of patients 
at risk of irreversible cardiotoxicity, thereby optimizing the benefits of protective therapy. Accordingly, the 
early-phase detection of subclinical AIC has become an important field of medical investigation7.
To elucidate the mechanisms involved in the cardiotoxic process, we aimed to map the cardiomyocyte 
response using an animal model of DOX-induced cardiotoxicity by four different mechanistic approaches. Since 
early apoptosis is characterized by changes in PS expression and activation of several intracellular regulatory pro-
teins, PS distribution was studied with 99mTc-Annexin V and correlated to histological apoptosis markers caspase 
3 and 8, p53, anti-apoptotic Bcl-2, and DNA fragmentation analysis. Cardiomyocyte (mitochondrial) membrane 
integrity (Δψm), which indicates later off-set apoptotic and necrotic changes, was assessed with 99mTc-sestamibi 
and 99mTc-glucaric acid and correlated to JC-1 fluorescent dye, Bcl-2, and DNA fragmentation. Furthermore, per-
fusion changes were studied using 99mTc-sestamibi and correlated to hypoxia-inducible factor (HIF-) 1α, which 
plays an important role in the molecular response to hypoxemic conditions8. Finally, glucose metabolism was 
evaluated by 18-fluorine-fluorodeoxyglucose ([18F]FDG) and correlated to HIF-1α, since the latter is suggested 
to activate glucose transporters (GLUT)9. A schematic overview of the studied markers and their place in the 
cardiotoxic process is provided in Fig. 1.
Materials and Methods
Study design. Figure 2 shows a schematic representation of the study design. Sixteen healthy male BALB/c 
mice were assigned to one of four radiopharmaceutical groups. Intraperitoneal (i.p.) administration of 15 mg/kg 
DOX was applied in all groups every three weeks for one, two, three, or four cycles, respectively. The maximum 
cumulative dose comprised 60 mg/kg given over 12 weeks, which corresponds to a potentially cardiotoxic dose of 
1050 mg per cycle for a 70-kg male patient10. At baseline and after completing each cycle of DOX, the cardiac and 
other organ biodistribution of the four radiopharmaceuticals was investigated approximately one hour after intra-
venous (i.v.) tail vein administration. After a group of four mice completed the regimen, the left ventricular (LV) 
function was evaluated by transthoracic echocardiography. Then animals were sacrificed for non-imaging assess-
ment, which included deoxynucleotidyl transferase biotin-dUTP nick-end labeling (TUNEL) staining, cardiac 
expression of Bcl-2, p53, caspase 3, caspase 8, and HIF-1α and Δψm by Western blot (WB) analysis, immunohis-
tochemistry (IHC), and fluorescence-activated cell sorting (FACS)/flow cytometry. Furthermore, a group of four 
healthy BALB/c mice per radiopharmaceutical served as controls, as they were treated at the same time-points 
and conditions with saline administration. They were also imaged after every cycle, but were only sacrificed after 
Figure 1. The studied cardiac markers in the process of AIC. DOX = doxorubicin, PS = phosphatyldiserine, 
NRG = neuregulin, GLUT = glucose transporter, ROS = reactive oxygen species.
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completing all four saline cycles. The study was approved by the animal care committee of the University of Pisa 
in accordance with relevant animal care guidelines.
Radiopharmaceutical preparation and administration. 99mTc-sestamibi. The lipophilic cation 
Sestamibi (Cardiolite, Bristol-Myers Squibb) was radiolabeled by adding water to 1–3 ml of sodium pertechne-
tate (99mTcO4)Na and heated for ten minutes at 100 °C. After cooling, a monovalent lipophilic cationic complex 
was retrieved (99mTc-sestamibi-6–2-metossi-isobutyl-isonitril), of which an average of 18.5 MBq in 0.1 mL was 
injected i.v.
99mTc-Annexin V. Human recombinant Annexin V (National Institutes of Health, Bethesda, MD, USA) 
was radiolabeled through combined in vitro incubation at room temperature for 30 minutes of 60–90 μg 
di-HYNIC-Annexin V diluted in 0.5 ml of physiological saline solution, 0.74–1.11 MBq pertechnetate anion 
(99mTcO4−), which was freshly eluted by a 6 GBq generator (Amersham, GE HealthCare), 10–20 μg of reduction 
agent (stannous chloride dehydrate, SnCl2−2H2O), and 1.5 mg of tricin (N-[tri(hydroxymethyl)methyl]glycine) 
as co-ligand. Labeling yield was 85–90%. 99mTc-Annexin V was then injected in a 0.1 mL solution containing on 
average 18.5 MBq of 99mTc-Annexin V, which corresponds to a total protein concentration of 4.5 ng per animal.
99mTc-glucaric acid. 99mTc-glucaric acid (Molecular Targeting Technologies, Inc. West Chester, PA, USA) was 
prepared from a lyophilized kit containing 12.5 mg of D-glucaric acid and 0.15 mg of stannous chloride11 by add-
ing 1480 MBq (40 mCi) freshly eluted 99mTc-pertechnetate as previously described12. Labeling efficiency (always 
>98%) was checked by ascending chromatography. The radiopharmaceutical was injected in 0.1 mL solution, 
containing on average 18.5 MBq 99mTc-glucaric acid.
[18F]FDG. The glucose analogue [18F]FDG was provided as a bulk vial (Gluscan, GE Healthcare), from which a 
sample of 18.5 MBq in 0.1 ml was injected. To avoid the intake of carbohydrates, the mice that received [18F]FDG 
were provided a fat-enriched diet.
Echocardiographic evaluation. LV function was evaluated with transthoracic echocardiography before 
the mice were euthanized, approximately 10 minutes after initiation of sedation. M-mode images were used for 
measurements of LV end-diastolic internal diameter (LVEDD) and LV end-systolic internal diameter (LVESD) in 
two consecutive beats. Fractional shortening (FS) was calculated as FS% = [(LVEDD − LVESD)/LVEDD] × 100.
Biodistribution and histological analysis. After completion of their regimen and one hour after injec-
tion of the radiopharmaceuticals, animals were anesthetized and sacrificed. For biodistribution studies, samples 
of thyroid, kidney, tail, bone, lung, heart, muscle, blood, stomach, skin, liver, spleen, intestine, and urine were 
removed and weighed immediately. Radioactivity of these samples was registered for 180 seconds by a gamma 
counter (2470 Automatic Gamma Counter Wizard, PerkinElmer, Waltham, MA, USA), along with an aliquot of 
the injective and the tail to correct for partial extravasation, expressed as a percentage of the injected dose per 
gram of tissue (%ID/g).
Before gamma counting, two three-millimeter cardiac tissue slices were obtained for histology: one was fro-
zen at −80 °C in dry ice and the other was placed in 4% formalin. After treatment with a protease inhibitor 
(1:100 in 10 mM Tris buffer, pH 8), apoptotic cells were assessed with direct fluorescence fragment end labeling 
of DNA breaks (TUNEL kit, Fluorescein FragEL, Calbiochem, San Diego, CA, USA). Caspase 3 and HIF-1α were 
immunostained using antihuman-mouse active antibodies (rabbit anti-caspase 3 and rabbit anti-HIF polyclonal 
antibody, Chemicon International, Temecula, CA, USA) after incubation with a fluorescent-labeled secondary 
antibody (Alexa Fluor 488 goat anti-rabbit IGg, Thermo Fisher Scientific, Waltham, MA, USA). Cells stained with 
TUNEL, caspase 3, and HIF-1α were counted in ten randomly selected high-power tumor fields (magnification 
x200) and expressed as a percentage of total cells. Furthermore, cardiac samples were analyzed by Western blot-
ting to identify the specific amount of Bcl-2, p53 (both Santa Cruz Biotechnology Inc., Dallas, TX, USA), caspase 
3, and caspase 8 (both Cell Signaling Technologies Inc., Danvers, MA, USA).
Measurement of Δψm. Inner Δψm was measured by a single fluorescent lipophilic cation 
5,5′,6,6′-tetrachloro- 1,1′,3,3′-tetraethylbenzimidazolocarbocyanine iodide (JC-1) that marks the loss of poten-
tial. For this purpose, mitochondria were isolated from myocardial tissue using a dedicated kit (Mytocondria 
Isolation Kit, Sigma-Aldrich, St. Louis, MO, USA) stained with JC-1 and analyzed by FACS (MACSQuant, 
Miltenyi Biotec, Bergisch Gladbach, Germany). JC-1, concentrated in the mitochondrial matrix of normal cells 
Figure 2. Schematic study design. Non-imaging markers are WB, IHC, and FACS expression markers. 
† = sacrifice of mice.
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due to the electrochemical potential gradient, forms red fluorescent aggregates. Any event that dissipates the 
mitochondrial membrane potential prevents the accumulation of the JC-1 dye in the mitochondria. Accordingly, 
red stained cells represent intact mitochondria, whereas when the dye is dispersed throughout the entire 
cell, a shift from red (J-aggregates) to green fluorescence (JC-1 monomers) is observed. A red-to-green (i.e., 
intact to disrupt mitochondrial) ratio was performed and described as upper and lower border (UR and LR). 
Consequently, a decreasing ratio was considered a disintegration of membrane potential.
statistical analysis. Biodistribution and immunofluorescent data are expressed as mean and median %ID/g 
tissue and standard deviation (SD). Data were analyzed by non-parametrical tests (Kruskal-Wallis and Dunn) 
to evaluate the differences in groups at different time points and by Mann-Whitney U to test the significance 
between DOX-treated and DOX-naïve mice. Furthermore, Spearman’s rho was used to assess correlations. 
Significance was set at p < 0.05. Statistics were performed using IBM SPSS 20 for Windows. The datasets gen-
erated and/or analyzed as part of the current study are available from the corresponding author by reasonable 
request.
Figure 3. Biodistribution of radiopharmaceuticals during treatment. At baseline and after one, two, three, or 
four cycles of DOX administration (corresponding to a dose of 15, 20, 45, or 60 mg/kg), expressed as %ID/g.
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Results
Doxorubicin treatment. A total of 64 DOX-treated and 16 DOX-naïve mice were examined. The mice that 
received up to three cycles (45 mg/kg) of DOX did not exhibit any significant side effects and appeared healthy. 
The mice that received four cycles (60 mg/kg) either died or showed significant side effects such as weight loss, 
edema, and alopecia.
Figure 4. Cardiac distribution of imaging and non-imaging markers at baseline and after DOX administration. 
(A) Radiopharmaceutical uptake. (B) WB markers Bcl-2, caspase 3 and 8, and p53. (C) IHC markers caspase 
3, TUNEL, and HIF-1α in percentage of positive cells. (D) Mitochondrial membrane potential markers. Upper 
and lower ratio (UR and LR).
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Echocardiography. FS assessment of DOX-treated and DOX-naïve mice did not show significant differ-
ences at cycles 1 and 2 (63.3 ± 6.1% and 64.8 ± 5.3%, respectively). At cycles 3 and 4, the average FS for the 
DOX-treated group decreased to 48.6 ± 4.5% and 42.1 ± 3.7%, respectively, whereas the average FS for the control 
groups remained invariable as compared to the baseline.
Cardiac and biodistribution of imaging biomarkers. The biodistribution of radiopharmaceuticals is 
shown in Figs 3–5 and summarized in Table 1.
99mTc-sestamibi. Maximal cardiac uptake of 99mTc-sestamibi was seen after two cycles of DOX, reaching a max-
imum dose of 12.0%, before dropping. Pairwise comparison returned an adjusted significance of p = 0.002 at 
two cycles. Other organs that displayed a peak dose at two cycles were the kidney and liver (13.5% and 13.7%, 
respectively). The measured dose in thyroid and intestinal tissue was considerable, peaking at one cycle (7.7%) 
and four cycles (7.1%), respectively.
Figure 5. Median cardiac uptake of radiopharmaceuticals in all treatment cycles, stratified according to 
treatment with DOX. The median uptake differed significantly between DOX-treated and DOX-naïve mice for 
all radiopharmaceuticals (p < 0.05, Mann Whitney U).
DOX status
Median uptake in % (SD)




5.06 (0.004) 11.97 (0.030) 5.09 (0.011) 5.02 (0.004) 0.007
Naïve 3.88 (0.003) 3.79 (0.002) 3.45 (0.002) 3.40 (0.002) ns




4.69 (0.008) 2.65 (0.003) 1.40 (0.001) 1.52 (0.002) 0.002
Naïve 0.82 (0.001) 0.90 (<0.001) 0.81 (0.002) 0.82 (0.001) ns




0.80 (0.001) 0.90 (0.001) 1.07 (0.001) 1.10 (0.001) 0.009
Naïve 0.63 (0.001) 0.70 (0.001) 0.88 (0.001) 0.87 (0.001) ns




4.00 (0.002) 4.22 (0.002) 4.28 (0.003) 4.18 (0.004) 0.03
Naïve 1.48 (0.001) 1.63 (0.002) 1.67 (0.002) 1.67 (0.002) ns
Difference 2.52* 2.59* 2.61* 2.51*
Median expression by WB (SD)
Bcl-2
Treated
3560 (773) 3305 (437) 2790 (246) 3850 (250) 4750 (189) 0.009
p53 1908 (79) 2395 (132) 2905 (358) 4565 (273) 5185 (189) 0.001
Caspase 3 1575 (234) 3815 (220) 3715 (208) 2255 (172) 2325 (211) 0.002
Caspase 8 1550 (173) 3420 (288) 2630 (215) 1895 (163) 1700 (335) 0.003
% of positive cells (median of 10 fields) by IHC (SD)
TUNEL 0.48 (0.14) 5.42 (0.64) 3.56 (0.31) 1.74 (0.20) 1.95 (0.24) 0.001
HIF-1α 0.22 (0.05) 0.36 (0.06) 0.29 (0.02) 0.44 (0.06) 0.27 (0.03) 0.005
Caspase 3 0.18 (0.04) 6.28 (0.58) 4.63 (0.40) 1.66 (0.64) 0.98 (0.23) 0.001
Table 1. Cardiac uptake of investigated markers. *p-value < 0.05 (Mann-Whitney U). †p-value (Kruskal-
Wallis). Bold = highest uptake in time; DOX = doxorubicin; SD = standard deviation; WB = Western blot; 
IHC = immunohistochemistry.
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99mTc-Annexin V. The maximal cardiac uptake of 99mTc-Annexin V was 4.7% after one cycle of treatment (adj. 
p = 0.001), gradually decreasing to approximately baseline value at four cycles. The highest organ doses were 
measured in the kidney (19.2%, one cycle), spleen (5.6%, one cycle), and liver (8.9%, two cycles). In other organs 
only small amounts of 99mTc-Annexin V were measured.
99mTc-glucaric acid. The kidney showed the highest uptake of 99mTc-glucaric acid, particularly at baseline and 
two cycles (both 9.0%). Cardiac uptake was the lowest compared to the other radiopharmaceuticals and did not 
show a significant increase with DOX dose. It peaked at four cycles (1.1%).
[18F]FDG. [18F]FDG uptake was the highest in the kidney, mainly after three and four cycles (6.4% and 6.3%). 
Cardiac uptake rose after one week to its peak at three cycles (4.3%, adj. p = 0.02). Other organs that displayed 
high uptake were bone (marrow), liver, and intestine (peak dose at four, four, and two cycles, respectively).
Cardiac expression of non-imaging markers. Bcl-2 expression reached its minimum at two cycles, 
although not significant, before increasing to the maximum at four cycles. Expression of p53 increased with 
dose, peaking at four cycles (adj. p = 0.001). Caspase 3 expression showed an identical trend by both WB and 
IHC measurement, peaking after the first cycle of DOX (with an adj. p = 0.004 and adj. p = 0.001, respectively), 
but decreasing with subsequent cycles to near baseline levels. Caspase 8 expression showed a similar trend, with 
a maximum at one cycle of DOX (adj. p = 0.007), before decreasing to baseline level. TUNEL also peaked at one 
cycle (adj. p = 0.001) and dropped with subsequent cycles, although it did not return to baseline level. HIF-1α 
showed an increase in percentage of positive cells and peaked at 0.45 after three cycles (adj. p = 0.004), then 
dropped to 0.27 at maximum DOX dose.
JC-1 expression, depicting Δψm, showed a decrease of UR during the first two cycles, shortly increased after 
three cycles, and subsequently decreased after the last cycle. The LR increased initially, but dropped after three 
cycles and then rose again during the last cycle.
Correlations. Table 2 shows the calculated Spearman’s ρ used to determine correlations between imaging and 
non-imaging markers, stratified according to the metabolic pathway. Most striking were the correlations between 
99mTc-Annexin V and the caspases and TUNEL (Fig. 6). Less strong, though significant, were the relationships 
between 99mTc-Annexin V and Bcl-2 (ρ-0.50), 99mTc-sestamibi and Bcl-2 (ρ-0.55), and 18F-FDG and HIF-1α (ρ 
0.60). JC-1 measurements were insufficient to calculate exact correlations.
Bcl-2
Caspase 3 




99mTc-Annexin V −0.50* 0.91† 0.89† 0.08 0.95† 0.92†
Late apoptosis
99mTc-sestamibi −0.55* 0.38





Table 2. Correlations of investigated markers stratified to studied mechanism. Correlations assessed by 
Spearman’s ρ. *p < 0.05. †p < 0.01. WB = Western blot; IHC = immunohistochemistry.
Figure 6. Scatter plot of 99mTc-Annexin V correlations (ρ > 0.80).
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Discussion
This is the first study that evaluated the cardiac response to anthracycline exposure from several mechanistic 
molecular viewpoints, including early and late apoptosis imaging, perfusion changes, and glucose metabolism by 
a combination of molecular imaging and histological biomarkers. As previously mentioned the drop of LV ejec-
tion fraction (LVEF) represents a late-phase phenomenon in the physiopathology of chemotherapy-induced car-
diotoxicity and has low sensitivity in the presence of subclinical myocardial dysfunction. Many patients present 
with histological evidence of anthracycline-related changes and normal resting LV function13. This evidence has 
led researchers to look to other methods for evaluating cardiac function, regardless of cardiac volume changes, to 
detect the earliest manifestation of cardiotoxicity. However, the pathologic mechanisms underlying cardiotoxicity 
remain unclear. The results of our study, which map the patterns of different radiopharmaceuticals as surrogate 
markers of specific metabolic pathways (i.e., glucose consumption and perfusion) induced by chemotherapeutic 
administration, provide a direction for future research.
PS expression. 99mTc-Annexin V allows apoptosis imaging by binding to PS molecules at the outer surface 
of apoptotic cell membranes7. The exposure and redistribution of PS marks the start of the apoptotic execution 
phase. Elevated myocardial expression in DOX-treated animals has been associated with the presence of cardiac 
oxidative stress14. In patients treated with Adriamycin, 99mTc-Annexin V imaging detected cardiomyocyte death 
at a lower dose and an earlier stage than echocardiography15.
In the current study, we observed a markedly increased expression of 99mTc-Annexin V after the first cycle 
of DOX. This suggests that apoptosis begins at low levels of anthracycline exposure. Bennink et al. observed 
a similar early rise of 99mTc-Annexin V uptake in rat hearts, also demonstrating a dose-dependent increase16. 
In contrast, we noted a decrease in 99mTc-Annexin V uptake with subsequent cycles of DOX. This finding was 
confirmed by a strong correlation between 99mTc-Annexin V and histological apoptosis markers caspase 3 and 8, 
which support a real reduction of apoptotic PS expression. Most likely, only a limited number of cardiomyocytes 
are prone to anthracycline-induced apoptosis, which already occurs at low cumulative dose. This selective induc-
tion of apoptosis in susceptible cardiomyocytes has been observed before by Bennink et al.16.
Our results indicate a strong relationship between TUNEL activity and 99mTc-Annexin V expression. This was 
different from that reported by Bennink et al.16. However, for adequate TUNEL activity measurement, cardiac 
tissue must be examined extensively and, as already suggested, TUNEL activity was undetectable, likely due to an 
insensitive method. Indeed, recent research has indicated that DNA degradation belongs to the earliest events of 
the apoptosis cascade5.
Membrane disintegration. Cell blebbing, shrinkage, and membrane disintegration occur during the late 
phase of the apoptotic cascade. 99mTc-glucaric acid (glucarate), binding positively charged nuclear histones in 
the intracellular domain after cardiomyocyte membrane disintegration, may be used as a marker of the mem-
brane disintegration. In contrast to the early apoptotic changes that can be reversed, cardiomyocyte membrane 
disintegration represents irreversible damage in necrotic cells17. This is illustrated by a distinct expression of 
99mTc-glucaric acid in necrosis, compared to the absence of 99mTc-glucaric acid signal in apoptotic cells, as demon-
strated by Khaw et al.18. We observed a discrete, though significant, elevation of 99mTc-glucaric acid compared 
to controls, which minimally but consistently increased with subsequent doses. Since irreversible cell damage 
is known to be dose-dependent, the observed trend of 99mTc-glucaric acid suggests that it actually depicts irre-
versible cardiomyocyte damage as shown by Okada et al.17, a finding of high potential in AIC. However, the 
differences were discrete and stratification into high- and low-risk groups by imaging method could therefore be 
problematic. Furthermore, we observed a (non-significant) increasing trend among control mice between base-
line and cycle four. This could mean that 99mTc-glucaric acid also depicts physiologic cell turnover. Additionally, 
fructose transporter GLUT-5 is suggested to mediate 99mTc-glucaric acid uptake in viable cells. This transporter 
is also present on murine cardiomyocytes; therefore, GLUT-5 upregulation in response to doxorubicin exposure 
may also play a role as well19,20. The extent of these effects is unknown and the interpretation of fluctuations in 
99mTc-glucaric acid uptake in particular is thus challenging and warrants additional research.
In addition to cardiomyocyte membrane disintegration, mitochondrial membrane integrity is compro-
mised in AIC. 99mTc-sestamibi, positively charged, is taken up in normal functioning cardiomyocytes due to 
a large negative mitochondrial transmembrane potential. It has been shown in vitro that, in response to clini-
cally relevant doxorubicin levels, opening of calcium-regulated transition pores in the mitochondrial membrane 
dissipates membrane potential21. Additionally, it has been suggested that monoclonal antibodies (e.g., trastu-
zumab) partly exert their cardiotoxic effect by reducing membrane potential22. In doxorubicin-treated patients, 
increased 99mTc-sestamibi uptake and retention in myocardial mitochondria has been observed23. In our study, 
DOX-treated animals showed a significant increase in cardiac uptake of 99mTc-sestamibi in two cycles, followed 
by a decrease during cycles three and four. This could be explained by the fact that mitochondrial membrane dis-
integration peaks at medium anthracycline exposure, a finding supported by the observation that Δψm dropped 
at two cycles. However, 99mTc-sestamibi kinetic is complex and influenced by some factors such as p-glycoprotein 
(p-gp) expression. P-gp is a membrane efflux transporter that pumps toxic substances, including DOX, out of 
cells. 99mTc-sestamibi is a known substrate for this protein24. When p-gp is upregulated in response to DOX 
exposure, as observed in murine cardiomyocyctes25, 99mTc-sestamibi uptake decreases accordingly. Unfortunately, 
we did not evaluate p-gp expression in our model and, to our knowledge, the relationship between p-gp and 
99mTc-sestamibi in cardiomyocytes has not been investigated before.
Perfusion changes. 99mTc-sestamibi uptake is also influenced by vascular changes that occur following anth-
racycline administration, which resemble the effects of ischemia, illustrated by both reversible and fixed defects23. 
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The observed decrease in 99mTc-sestamibi could therefore also reflect blood perfusion changes dominating the 
above-mentioned mechanisms in case of high cumulative DOX doses. To clarify this point, it could be helpful to 
evaluate the uptake patterns of other ischemia tracers such as 82-Rubidium, which are incorporated into cardio-
myocytes by a different transporter than 99mTc-sestamibi26.
Glucose metabolism. In the current study, we observed a progressive increase in [18F]FDG directly after 
commencing anthracycline treatment, which remained stable during subsequent doses of DOX. Enhanced [18F]
FDG uptake in anthracycline-exposed cardiomyocytes may rely on a neuregulin (NRG)-mediated response. NRG 
is a protein secreted by the endocardium and endothelium of cardiac vasculature that might protect against AIC 
and, as an adaptive pattern, enhances glucose metabolism of the heart27. However, since the magnitude of [18F]
FDG changes over time is of borderline significance and the potential NRG effect on [18F]FDG has not yet been 
explored, further research in this field is needed. Based on the hypothesis that patients with higher baseline NRG 
expression exert a better adaptive response to anthracyclines, low cardiac [18F]FDG uptake after anthracycline 
therapy could be used to identify individuals at high risk of developing AIC during the early phase of the pro-
cess28. Such variable [18F]FDG uptake patterns have been observed in anthracycline-treated lymphoma patients29. 
Additionally, [18F]FDG can be used to assess cardiomyocyte viability, since intact cardiomyocytes utilize glucose 
for cell functions. Consequently, cardiomyocyte decay is accompanied by decreased glucose uptake. However, it 
should be noted that [18F]FDG application in this clinical setting requires adequate patient preparation to reduce 
the physiological uptake of [18F]FDG of the myocardium. The increased cardiac uptake of [18F]FDG through-
out the cumulative anthracycline administration in our study suggests a reversible mechanism, since apoptosis 
apparently does not induce cell death. This is also underlined by the discrete increase of 99mTc-glucaric acid, which 
indicates only a limited amount of irreversible cell disintegration.
We observed a strong correlation between [18F]FDG and HIF-1α—the latter being a hypoxia-driven tran-
scription factor that regulates the expression of a variety of genes in response to a lack of oxygen8. Recently, Seino 
et al. reported a similar relationship in benign abdominal tumors9. They suggested that HIF-1α expression is 
enhanced directly after exposure to hypoxia and subsequently activates GLUT-1 and GLUT-3, hexokinase, vascu-
lar endothelial growth factor, and several glycolytic enzymes. Furthermore, since maximal [18F]FDG uptake and 
HIF-1α expression were located in areas of increased cellularity, but decreased vascularity, [18F]FDG accumula-
tion is not influenced by increased vascular availability or endothelial dysfunction of the radiopharmaceutical, 
but results from promoting glucose uptake mechanisms as an adaptive mechanism.
Our findings indicate that [18F]FDG can be used not only to stratify patients into low- and high-risk groups, 
but also to detect reversibility without being influenced by vascular availability. This is of major importance for 
guiding protective therapy. It provides an interesting opportunity for clinical use, since [18F]FDG is now widely 
available and used extensively. Another major advantage of [18F]FDG above other imaging markers is that the 
accumulation can be assessed quantitatively using standard uptake value (SUV), which provides an independent 
inter-patient and follow-up method.
Conclusion
In conclusion, this study demonstrated that the cardiac response to anthracyclines at low doses starts with apop-
tosis depicted by 99mTc-Annexin V and confirmed by histological apoptosis markers. Late apoptotic and necrotic 
changes, such as membrane disintegration, can potentially be detected by 99mTc-sestamibi and 99mTc-glucaric 
acid. However, 99mTc-sestamibi uptake is influenced by other mechanisms, including p-gp expression and vas-
cular changes, which complicates interpretation of observed uptake patterns. 99mTc-glucaric acid uptake differed 
slightly from controls, which implies a problematic differentiation between high and low cardiac toxicity risk. 
[18F]FDG uptake signifies an early adaptive response to DOX and has the highest potential to serve as a clinically 
exploitable early marker of reversible cardiotoxicity in the near future.
Data Availability
Data for reproduction is available through the corresponding author.
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